S&P 500
6,000.36
+1.0%
+$61.06
DJI
42,762.87
+1.0%
+$443.13
NASDAQ
19,529.95
+1.2%
+$231.50
Bitcoin
104,903.00
+1.1%
+1,139.21
AAPL
$204.23
+1.8%
+$3.60
AMZN
$213.68
+2.8%
+$5.77
GOOG
$174.93
+3.0%
+$5.12
META
$698.00
+2.0%
+$13.38
MSFT
$470.38
+0.6%
+$2.70
NVDA
$141.76
+1.3%
+$1.77
TSLA
$295.66
+3.8%
+$10.96
Motley Fool Staff
the_motley_fool
Recent Articles by Motley Fool Staff

Jul 14, 2016
by Motley Fool Staff
Why Is "Waiting for a Target Price Point" Good, but "Market Timing" Bad?
The Fools always caution against market timing, because it’s a great way to miss out on rallies and lock in loses. So one reader wants to know why we suggest waiting for so-called attractive price points to buy.

Jul 13, 2016
by Motley Fool Staff
Why Investors Are Underestimating Gilead Sciences
Gilead may be experiencing a slowdown in sales of its key hepatitis C drugs, but there are some intriguing potential revenue drivers coming down the pipeline that the market doesn't seem to be factoring into its share price.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.